The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and ...

The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...

New psoriasis drug Zoryve approved. How to use & why Black American participation in clinical trials is vital for health ...

The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild ... cleared psoriasis plaques on the ...

Roflumilast was well-tolerated, with mild adverse reactions ... “In clinical trials, Zoryve foam not only effectively cleared psoriasis plaques on the body and scalp but also provided rapid ...

TUESDAY, May 27, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Zoryve (roflumilast) topical foam 0.3 percent for the treatment of plaque psoriasis of the scalp and ...

New data from the Phase 3 INTEGUMENT-OLE long-term open label study show durable improvement in the signs and symptoms of atopic dermatitis (AD), including almost half of participants achieving no or ...

“In clinical trials, ZORYVE foam not only effectively cleared psoriasis plaques on the body and scalp ... adolescents ages 12 years and older with mild to severe plaque psoriasis of scalp ...

“In clinical trials, ZORYVE foam not only effectively cleared psoriasis plaques on the body and scalp ... adolescents ages 12 years and older with mild to severe plaque psoriasis of scalp ...

assesses the severity of hand and foot psoriasis using a 5-point scale to score the plaques on the hands and feet as: clear (0), almost clear (1), mild (2), moderate (3) and severe (4). Dr. Melinda ...

Newseria nie ponosi odpowiedzialności za treści oraz inne materiały (np. infografiki, zdjęcia) przekazywane w „Biurze Prasowym”, których autorami są zarejestrowani użytkownicy tacy jak agencje PR, ...